Effectiveness of riboflavin as prophylaxis of paediatric migraine

International Journal of Contemporary Pediatrics Kumaran MAR. Int J Contemp Pediatr. 2023 Dec;10(12):1881-1885 http://www.ijpediatrics.com pISSN 2349-3283 | eISSN 2349-3291

DOI: https://dx.doi.org/10.18203/2349-3291.ijcp20233545

Review Article

Effectiveness of riboflavin as prophylaxis of paediatric migraine

Mithun A. R. Kumaran*

Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, United Kingdom Received: 25 October 2023 Revised: 09 November 2023 Accepted: 10 November 2023 *Correspondence: Dr. Mithun A. R. Kumaran, E-mail: mithun.kumaran1@nhs.net Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT Paediatric migraine headache is a common condition for which there is no general consensus on the choice of prophylactic. Riboflavin has been considered as a potential prophylactic which is well tolerated. This review examines the current literature regarding the efficacy of riboflavin as a prophylactic. There have been mixed results from both retrospective studies as well as randomised controlled trials. Whilst the adverse effect profile is minimal compared to other migraine prophylactics, further well-designed studies with larger sample sizes and longer follow- up are required. Keywords: Migraine, Prophylaxis, Paediatric, Riboflavin

INTRODUCTION

Migraine headache is a common condition affecting both children and adults. It has an estimated prevalence of almost eight percentages in children.1 The treatment strategy is broken into acute symptomatic relief and prophylaxis. An effective prophylactic should decrease the frequency, intensity and disabling effect on the function.

Riboflavin has an important role in mitochondrial energy production since it is a precursor for flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN). Both FAD as well as the FMN regulate flavoenzymes which help to protect the cell from oxidative stress and apoptosis.2 It has been suggested that there is mitochondrial dysfunction in the migraine patients following brain energy metabolism studies.3 This has provided the theoretical framework for the use of riboflavin in the prophylaxis of migraine headache. This review will examine the current literature on the prophylactic effect of the riboflavin on the paediatric migraine headache.

LITERATURE SEARCH

A literature search using the below criteria was performed in the PubMed database up to 2023. PubMed: (migraine OR headache) AND (riboflavin OR B2 OR vitamin B2) AND (prophylaxis OR prophylactic) AND (children OR adolescent OR pediatric OR pediatric) 31 results, 8 relevant.

DISCUSSION

Two double-blind, placebo-controlled RCTs showed no significant difference in the reduction of migraine frequency.4,6 When higher dose riboflavin (200 mg/day)

was used, 66.6% in the placebo group reported 50% or greater reduction in migraine frequency compared to 44.4% in riboflavin group (p=0.125) after three months.1 In the lower dose riboflavin (50 mg/day) RCT, 3.60 headaches/month reduced to 2.05 in the riboflavin group whilst 3.05 reduced to 1.4 in the placebo group (p=0.44) after ten months.6

International Journal of Contemporary Pediatrics | December 2023 | Vol 10 | Issue 12 Page 1881

Source table

Kumaran MAR. Int J Contemp Pediatr. 2023 Dec;10(12):1881-1885

Initial positive results were reported in a retrospective study of 41 participants where there was significant reduction in migraine frequency after three months (21.7 to 13.2, p<0.01).8 But there was no significant reduction in migraine frequency after six months (19.3 to 11.4, p>0.05). Furthermore, this study compared different doses of riboflavin (200 mg/day vs 400 mg/day) but found no significant difference. This study is limited by the lack of a placebo group and it is known that the placebo effect is highly variable in migraine studies.5 A further recent retrospective study has also shown a significant reduction in migraine frequency (21.9 to 11.07 headache days/month, p<0.0001).11 Furthermore, this study used twice-daily weight-based riboflavin which may be theoretically more efficacious since the half-life of riboflavin is one to 2 hours.12 But in a similar fashion to Condo et al this study is limited by a lack of placebo.8

The first positive result in a double-blind, placebo- controlled RCT was by Athaillah et al.7 In 98 participants, there was a significant reduction in headaches/month in the riboflavin group after three months (6 to 3.7) compared to the placebo group (5.0 to 4.9, p=0.029). Two important aspects are regarding the

dose of riboflavin and the design of the study. The RCT used a higher dose of riboflavin (400 mg/day) compared to previous RCTs and this may have contributed to the significant result. Although this would differ from the retrospective study by Condo et al which reported no statistical difference between 200 mg/day and 400 mg/day.8 Furthermore, there were increased adverse effects reported in this RCT. For example, polyuria was found in 36% of participants in the riboflavin group. Regarding the design of the RCT, it was not stated if there were statistically significant differences between groups in terms of baseline characteristics. For example, the placebo group had 6 males compared to 21 males in the riboflavin group.

The most recent RCT to provide a positive result looked at 90 participants using 100 mg/day or 200 mg/day riboflavin after three months.10 There was a significant reduction in migraine frequency in the 200 mg/day group (9.27 to 2.87) compared to placebo (8.20 to 8.17, p=0.000). There was no significant difference between the 100mg/day group compared to placebo and so this is the first study to show a dose-dependent effect of riboflavin.

Table 1: Review of riboflavin prophylaxis studies.

Continued.

International Journal of Contemporary Pediatrics | December 2023 | Vol 10 | Issue 12 Page 1882

Source reviewed table

Kumaran MAR. Int J Contemp Pediatr. 2023 Dec;10(12):1881-1885

Continued.

International Journal of Contemporary Pediatrics | December 2023 | Vol 10 | Issue 12 Page 1883

Source table

Kumaran MAR. Int J Contemp Pediatr. 2023 Dec;10(12):1881-1885

HIS-International headache society, PedMIDAS-paediatric migraine disability assessment, RCT-randomised controlled trial.

CONCLUSION

There is currently inconclusive evidence regarding the role of riboflavin as a prophylactic to reduce migraine frequency in children and adolescents. Whilst there have been positive results in both retrospective studies and RCTs, a longer follow-up than the standard three months is required to examine the sustained effect of riboflavin. Furthermore, from a pharmacokinetic standpoint the half- life of riboflavin is one to two hours which poses the question of whether a twice-daily regimen would be more successful. Minimal adverse effects have been reported with lower doses of riboflavin which contrasts with other migraine prophylactics. More extensive placebo- controlled trials with larger samples sizes and longer follow-up are required to further examine the efficacy of riboflavin for prophylaxis of paediatric migraine headache.

Funding: No funding sources Conflict of interest: None declared Ethical approval: Not required

REFERENCES

1. Abu-Arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol. 2010;52(12):1088- 97. 2. Wanders RJ, Ruiter, JP, IJLst L, Waterham HR, Houten SM. The enzymology of mitochondrial fatty acid beta-oxidation and its application to follow-up

analysis of positive neonatal screening results. J Inherit Metab Dis. 2010;33(5):479-94. 3. Welch KM, Levine SR, D'Andrea G, Schultz LR, Helpern JA. Preliminary observations on brain energy metabolism in migraine studied by in vivo phosphorus 31 NMR spectroscopy. Neurology. 1989;39(4):538-41. 4. MacLennan SC, Wade FM, Forrest KM, Ratanayake PD, Fagan E, Antony J. High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. J Child Neurol. 2008;23(11):1300-4. 5. Macedo A, Baños JE, Farré M. Placebo response in the prophylaxis of migraine: a meta- analysis. European J Pain. 2008;12(1):68-75. 6. Bruijn J, Duivenvoorden H, Passchier J, Locher H, Dijkstra N, Arts WF. Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double- blind, cross-over trial. Cephalalgia An Int J Headache. 2010;30(12):1426-34. 7. Athaillah YD, Saing JH, Saing HB, Lelo A. Riboflavin as migraine prophylaxis in adolescents. Paediatrica Indon. 2012;52(3):132‐7. 8. Condò M, Posar A, Arbizzani A, Parmeggiani A. Riboflavin prophylaxis in pediatric and adolescent migraine. J Headache Pain. 2009;10(5):361-5. 9. Thompson DF, Saluja HS. Prophylaxis of migraine headaches with riboflavin: A systematic review. J Clin Pharmacy Therap. 2017;42(4):394-403. 10. Talebian A, Soltani B, Banafshe HR, Moosavi GA, Talebian, M, Soltani S. Prophylactic effect of riboflavin on pediatric migraine: a randomized,

International Journal of Contemporary Pediatrics | December 2023 | Vol 10 | Issue 12 Page 1884

Kumaran MAR. Int J Contemp Pediatr. 2023 Dec;10(12):1881-1885

double-blind, placebo-controlled trial. Electronic Physician J. 2018;10(2):6279-85. 11. Das R, Qubty W. Retrospective Observational Study on Riboflavin Prophylaxis in Child and Adolescent Migraine. Pediatr Neurol. 2020;114:5-8. 12. Zempleni J, Galloway JR, McCormick DB. Pharmacokinetics of orally and intravenously

administered riboflavin in healthy humans. Am J Clin Nutr. 1996;63(1):54-66.

Cite this article as: Kumaran MAR. Effectiveness of riboflavin as prophylaxis of paediatric migraine. Int J Contemp Pediatr 2023;10:1881-5.

International Journal of Contemporary Pediatrics | December 2023 | Vol 10 | Issue 12 Page 1885